Valuation: CORESTEMCHEMON Inc.

Market Cap	98.04B 72.28M 63.79M 60.35M 54.74M 103M 6.94B 104M 724M 279M 3.54B 271M 266M 11.4B	P/E 2024	-3.45x	P/E 2025	-2.05x
Enterprise Value	129B 94.96M 83.8M 79.29M 71.91M 135M 9.11B 136M 951M 367M 4.65B 357M 349M 14.97B	EV / Sales 2024	4.76x	EV / Sales 2025	5.59x
Free-Float	81.23%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news: CORESTEMCHEMON Inc.

07-19	CORESTEMCHEMON Inc. Announces South Korea's MFDS Allows Neuronata-R to Remain on Market, Preserving Conditional Approval for Als Treatment	CI
12-18	Corestemchemon Advances Toward Als Stem Cell Commercialization with Regulatory Progress in Korea and Nsf-Backed U.S. Expansion	CI
22/09/25	CORESTEMCHEMON Inc.(KOSDAQ:A166480) dropped from S&P Global BMI Index	CI
18/09/25	Neuronata- Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway	CI
21/07/25	Corestemchemon to divest 2.7 billion won worth of own shares	RE
21/07/25	CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services	CI
29/05/25	Corestemchemon Announces Neuronata-R®? Stem Cell Therapy Shows Promise in Als Phase 3 Subgroup Analysis, Moves Toward Fda Accelerated Approval	CI
29/05/25	Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis	RE
07/05/25	Corestemchemon To Divest 3.4 Billion Won Worth Of Own Shares	RE
26/03/25	Corestemchemon To Divest 3.6 Billion Won Worth Of Own Shares	RE
23/09/24	CORESTEMCHEMON Inc.(KOSDAQ:A166480) added to S&P Global BMI Index	CI
26/03/24	CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	CI
22/03/24	CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor	CI

More news

Managers and Directors: CORESTEMCHEMON Inc.

Manager	Title	Age	Since
Gil-Ahn Yang CEO	Chief Executive Officer	70	-
Si-Hwan Song PSD	President	65	01/08/2000
Gwang-Soon Kwon PSD	President	54	-

Director	Title	Age	Since
Gyeong-Sook Kim BRD	Director/Board Member	61	16/06/2015
Gwang-Soon Kwon BRD	Director/Board Member	54	-
Gil-Ahn Yang BRD	Director/Board Member	70	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CORESTEMCHEMON INC.	+1.38%	+6.76%	+25.93%	-65.03%	71.3M
WUXI APPTEC CO., LTD.	+4.16%	-0.30%	+58.96%	+94.17%	71.53B
ARGENX SE	-0.19%	+1.32%	+37.20%	+81.33%	60.12B
LONZA GROUP AG	-1.51%	+2.39%	+9.10%	+36.79%	48.85B
IQVIA HOLDINGS INC.	+0.83%	+1.02%	+42.46%	+39.56%	44.28B
REVOLUTION MEDICINES, INC.	+1.86%	+8.89%	+344.74%	+693.64%	43.83B
BEONE MEDICINES AG	+2.22%	+2.09%	+9.37%	+108.76%	41.53B
CELLTRION, INC.	-0.67%	-0.45%	+4.47%	+46.37%	30.13B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.46%	+41.54%	+22.78%	27.98B
INSMED INCORPORATED	-0.01%	-2.18%	-19.62%	+356.29%	25.25B
Average	+1.35%	+1.11%	+55.42%	+141.47%	39.36B
Weighted average by Cap.	+1.44%	+0.63%	+63.73%	+155.29%

See all sector performances

Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The Company operates its business through two segments. The Non-clinical Contract Research Organization (CRO) Business segment is engaged in the provision of research and development services such as toxicity (safety) verification and drug efficacy (efficacy) verification in the non-clinical stage. The Cell Therapy Business segment is engaged in the development, production and sale of Lou Gehrig's disease treatments such as Neuronata-R.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/09/26	₩2,210.00	+1.38%	112,484
29/09/26	₩2,180.00	-0.68%	45,326
28/09/26	₩2,195.00	+3.29%	143,189
23/09/26	₩2,125.00	+2.66%	99,187
22/09/26	₩2,070.00	0.00%	74,305

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 30/09/2026			5-day change	1st Jan Change
2,210.00 ^KRW	+1.38%		+6.76%	+19.59%

1 day	+1.38%
1 week	+6.76%
Current month	+5.24%
1 month	+8.33%
3 months	+1.61%
6 months	-12.82%
Current year	+19.59%

1 week	2,125	2,290
1 month	1,987	2,400
Current year	1,642	6,100
1 year	1,014	6,100
3 years	1,014	15,610
5 years	1,014	20,550
10 years	1,014	34,350

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
02/05/25	Tae-Yong Lee	Sell	Chief Technology Officer	64,262	0.1955%
02/05/25	Gwang-Soon Kwon	Sell	Chairperson	151,072	0.4596%
07/10/24	Ryeong Lee	Others		1,875	0.0057%	-

	2024	2025
Net sales	28.76B 21.21M 18.71M 17.71M 16.06M 30.11M 2.03B 30.4M 212M 81.87M 1.04B 79.63M 77.9M 3.34B	20.16B 14.86M 13.12M 12.41M 11.26M 21.1M 1.43B 21.31M 149M 57.38M 728M 55.81M 54.6M 2.34B
Net income	-26.25B -19.36M -17.08M -16.16M -14.66M -27.48M -1.86B -27.75M -194M -74.72M -948M -72.68M -71.1M -3.05B	-26.83B -19.78M -17.46M -16.52M -14.98M -28.09M -1.9B -28.36M -198M -76.38M -969M -74.29M -72.67M -3.12B
Net Debt	42.32B 31.21M 27.54M 26.06M 23.63M 44.3M 2.99B 44.74M 313M 120M 1.53B 117M 115M 4.92B	30.76B 22.68M 20.01M 18.94M 17.17M 32.2M 2.18B 32.51M 227M 87.55M 1.11B 85.16M 83.3M 3.58B

CORESTEMCHEMON Inc. Stock

Stocks

A166480

KR7166480004

Biotechnology & Medical Research

Valuation: CORESTEMCHEMON Inc.

Chart: CORESTEMCHEMON Inc.

Latest news: CORESTEMCHEMON Inc.

Quotes and Performance

Price Extremes

Managers and Directors: CORESTEMCHEMON Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes